pirfenidone has been researched along with concanavalin a in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 2 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| El-Agamy, DS | 1 |
| Abdel-Aziz, AH; Abdelghany, TM; Ashour, AA; Salah, MM; Salama, SA | 1 |
2 other study(ies) available for pirfenidone and concanavalin a
| Article | Year |
|---|---|
Pirfenidone ameliorates concanavalin A-induced hepatitis in mice via modulation of reactive oxygen species/nuclear factor kappa B signalling pathways.
Topics: Animals; Antioxidants; Biomarkers; Chemical and Drug Induced Liver Injury; Concanavalin A; Cytoprotection; Disease Models, Animal; Hepatitis, Autoimmune; Liver; Male; Mice; NF-kappa B; Oxidative Stress; Pyridones; Reactive Oxygen Species; Signal Transduction | 2016 |
Pirfenidone alleviates concanavalin A-induced liver fibrosis in mice.
Topics: Animals; Collagen Type II; Collagen Type IV; Concanavalin A; Disease Models, Animal; Hepatic Stellate Cells; Liver; Liver Cirrhosis; Male; Matrix Metalloproteinase 2; Mice; Mice, Inbred BALB C; Pyridones; RNA, Messenger; Tissue Inhibitor of Metalloproteinase-1; Transforming Growth Factor beta; Tumor Necrosis Factor-alpha | 2019 |